Rempe Torge, Carlson Aaron, Miravalle Augusto, Gyang Tirisham Victoria
Department of Neurology, College of Medicine, University of Florida, Gainesville, USA.
Department of Neurosciences, School of Medicine, University of California San Diego, La Jolla, USA.
Mult Scler J Exp Transl Clin. 2020 Sep 25;6(3):2055217320960510. doi: 10.1177/2055217320960510. eCollection 2020 Jul-Sep.
To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients.
Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initiation of ocrelizumab.
No significant change in anti-JCV AI titers was observed 458 ± 300 days after initiation of ocrelizumab (n = 45, 0.7 ± 2.21 vs. 0.6 ± 2.06, p = 0.8). Seroconversion occurred in 1/20 initially anti-JCV seronegative patients. There was no correlation between changes in anti-JCV AI and immunoglobulins.
Treatment with ocrelizumab is not associated with an increase in anti-JCV AI titers.
前瞻性评估奥瑞珠单抗治疗的多发性硬化症（MS）患者的抗约翰·坎宁安病毒（JCV）抗体指数（AI）及其与免疫球蛋白水平的关系。
一项为期24个月的单中心前瞻性观察性研究，评估奥瑞珠单抗治疗前和治疗后MS患者的抗JCV AI和免疫球蛋白水平。
奥瑞珠单抗治疗458±300天后，抗JCV AI滴度无显著变化（n = 45，0.7±2.21对0.6±2.06，p = 0.8）。1/20例最初抗JCV血清阴性的患者发生了血清转化。抗JCV AI的变化与免疫球蛋白之间无相关性。
奥瑞珠单抗治疗与抗JCV AI滴度升高无关。
